The Valhalla Foundation awarded Octave Bioscience funding to further develop a biomarker blood test for assessing disease ...

In a large PPMS population that included older patients and people with more advanced disease, ocrelizumab led to a 30% risk ...

Already approved for progressive multiple sclerosis, ocrelizumab in a second phase 3 study demonstrates meaningful clinical ...

With FDA-requested toxicology reports in hand, Quantum is preparing to seek clearance for stating the first trial of Lucid-MS ...

A blood test might predict when multiple sclerosis patients are about to suffer a relapse in their symptoms, a new study says. Blood levels of a protein called neurofilament light chain rise ...